ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Synthetic Biologics has joined with French biotech firm Enterome Bioscience to test β-lactam antibiotics in the presence of Synthetic Biologics’ drug candidate SYN-004 for the treatment of Clostridium difficile, a hard-to-treat bacterium that can infect the human gut, causing colitis (see page 9). The firms plan to begin testing the combination in a Phase I trial on 100 patients beginning next month. Separately, Glasgow, Scotland-based MGB Biopharma has been awarded $2.2 million from the Technology Strategy Board, a U.K. government agency, to fund Phase I trials for MGB-BP-3, its drug candidate for treating C. difficile. MGB plans to begin trials by early 2015.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter